CompBrief BY VELARION

Companies Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals CEO salary & total pay, FY2022: $204K

Eiger BioPharmaceuticals (EIGR) CEO salary, fiscal 2022: David Apelian was paid a salary of $30,875 and $204,386 in total compensation. Free brief. Every figure links to the company’s own filing.

Eiger BioPharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2022.

All products and prices

David Apelian's complete compensation dossier

A PDF and a CSV sent to your email: David Apelian's pay in every fiscal year Eiger BioPharmaceuticals, Inc. reported it, line by line, with David Apelian's equity grants and Eiger BioPharmaceuticals, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$204,386CEO David Apelian · source
Say-on-pay support38.72%Latest vote · source

CEO pay, last three years

  • $3,504,020FY2021
  • $204,386FY2022

CEO total pay was $204,386 in fiscal 2022 (David Apelian), down from $3,504,020 in fiscal 2021 (David Cory, the CEO that year).

FY2022: salary $30,875 · bonus $0 · stock awards $0 · option awards $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Eiger BioPharmaceuticals, Inc. in fiscal 2022?
As disclosed, David Cory (Former President and Chief Executive Officer) was the highest-paid executive at Eiger BioPharmaceuticals, Inc. in fiscal 2022, with total compensation of $3,683,861.
How did shareholders vote on Eiger BioPharmaceuticals, Inc.'s executive compensation?
As disclosed, 38.72% of shareholders supported Eiger BioPharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Eiger BioPharmaceuticals, Inc. spend in total on board compensation for fiscal 2022?
As disclosed, Eiger BioPharmaceuticals, Inc. reported total board compensation of $701,600 for fiscal 2022.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
David Cory$649,106$0$239,700$895,884$376,200$0$1,522,971$3,683,861
Former President and Chief Executive Officer
Sriram Ryali500,0000122,400455,913200,000013,6331,291,946
Former Chief Financial Officer
Eldon Mayer410,000081,600312,444172,20004,763981,007
Executive Vice President and Chief Commercial Officer
David Apelian30,87500000173,511204,386
Interim Chief Executive Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2022 totalFY2021 totalFY2020 totalΔ FY2021→2022
David Cory$3,683,861$3,504,020—↑ +179,841
Sriram Ryali1,291,9462,050,365—↓ −758,419
Eldon Mayer981,0071,230,265—↓ −249,258
David Apelian204,386———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation policies are designed to attract and retain talented and skilled executives by paying for performance and to align the compensation of executives with the interests of stockholders through a mix of short-term and long-term compensation. Equity grants are utilized to create an ownership culture and align executive interests with stockholders, while time-based vesting features promote executive retention.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2022

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
David ApelianOPTION2022-03-11——12,000——
David CoryOPTION2022-03-11——263,436——
Eldon MayerOPTION2022-03-11——17,011——
Eldon MayerOPTION2022-03-11——80,989——
Sriram RyaliOPTION2022-03-11——134,061——

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2022

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
David ApelianOption2,4606,90714.31—
David ApelianOption9,0003,0005.1—
David ApelianRSU—6,000—7,080
David ApelianOption25,000—10.75—
David ApelianOption25,022—13.7—
David ApelianOption124,978—13.7—
David ApelianOption27,750—9.5—
David ApelianOption9,250—9.5—
David ApelianOption101,133—14.31—
David ApelianOption10,000—5.6—
David ApelianOption10,000—9.99—
David CoryOption—6,98814.31—
David CoryOption187,5005,51214.31—
David CoryOption—14,3755.6—
David CoryOption158,12557,5005.6—
David CoryOption—11,9619.99—
David CoryOption122,937146,1029.99—
David CoryRSU—31,333—36,973
David CoryOption23,02025,7308.15—
David CoryPSU—30,000—35,400
David CoryRSU—47,000—55,460
David CoryOption—17,5645.1—
David CoryOption52,687210,7495.1—
David CoryOption17,504—1.38—
David CoryOption56,889—1.38—
David CoryOption74,393—2.06—
David CoryOption261,437—15.89—
David CoryOption24,554—15.89—
David CoryOption8,313—11.75—
David CoryOption124,687—11.75—
David CoryOption10,770—9.5—
David CoryOption179,230—9.5—
Eldon MayerOption66,18425,99312.36—
Eldon MayerOption11,2579,81112.36—
Eldon MayerOption31,17129,4829.99—
Eldon MayerOption—10,5979.99—
Eldon MayerRSU—7,916—9,341
Eldon MayerOption8,2639,2378.15—
Eldon MayerPSU—30,000—35,400
Eldon MayerRSU—16,000—18,880
Eldon MayerOption117,0105.1—
Eldon MayerOption18,37462,6155.1—
Eldon MayerOption12,492—13.7—
Eldon MayerOption4,996—9.5—
Eldon MayerOption4,996—14.31—
Sriram RyaliOption—20,3135.6—
Sriram RyaliOption42,65640,1189.99—
Sriram RyaliOption—14,7269.99—
Sriram RyaliRSU—10,833—12,783
Sriram RyaliOption—4,6088.49—
Sriram RyaliOption34,43747,9558.49—
Sriram RyaliOption14,16615,8348.15—
Sriram RyaliPSU—30,000—35,400
Sriram RyaliRSU—24,000—28,320
Sriram RyaliOption—8,9395.1—
Sriram RyaliOption26,812107,2495.1—
Sriram RyaliOption38,240—10.46—
Sriram RyaliOption51,760—10.46—
Sriram RyaliOption44,687—5.6—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Thomas Dietz, Ph.DIndependent · Board Chair · Compensation · Nominating and Governance · Audit (Chair)$170,000$30,600$73,980——$274,580
Lisa Kelly-CroswellIndependent · Nominating and Governance · Newly elected22,5000158,568——181,068
Evan Loh, M.DIndependent · Compensation (Chair) · Nominating and Governance69,50030,60036,990——137,090
Amit K. Sachdev, J.DIndependent · Compensation · Nominating and Governance (Chair)67,50030,60036,990——135,090
Jeffrey Glenn, M.D., Ph.DIndependent · Audit · Compensation67,00030,60036,990——134,590
Christine Murray, M.S., R.A.CIndependent · Audit · Nominating/Governance64,50030,60036,990——132,090
Kim Sablich, M.B.AIndependent · Audit57,00030,60036,990——124,590

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)22,500 / 17,000 / 12,500
Stock ownership guideline—

Total cost of the board

ComponentFY2022
Cash retainers and fees$518,000
Equity awards (grant-date value)$183,600
All other compensation$0
Total cost of the board$701,600

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Eiger BioPharmaceuticals as a peer

Companies that benchmark against EIGR

The list of companies that name EIGR as a peer is temporarily unavailable — recheck shortly.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Eiger BioPharmaceuticals, Inc.2022David Apelian$30,875$0$0$0$204,386

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20232023-06-159,827,47615,512,01443,82238.72%Failed
20222022-06-1616,752,9449,086,605333,71864.01%Passed
20212021-06-1419,555,119773,615199,59895.26%Passed
20202020-06-1515,873,661285,634151,07097.32%Passed
20192019-06-11—————
20182018-06-12—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20232023-06-1538.72%a
20222022-06-1664.01%b
20212021-06-1495.26%c

a. Approved under the standard stated in the filing — “Approval on an advisory basis of the compensation of the Company's named executive officers -- "For" votes from the holders of a majority of shares present virtually or represented by proxy and entitled to vote on the matter | Abstentions: Against”.

b. Approved under the standard stated in the filing — “Approval on an advisory basis of the compensation of the Company's named executive officers -- "For" votes from the holders of a majority of shares present virtually or represented by proxy and entitled to vote on the matter | Abstentions: Against”.

c. Approved under the standard stated in the filing — “Approval on an advisory basis of the compensation of the Company's named executive officers -- "For" votes from the holders of a majority of shares present virtually or represented by proxy and entitled to vote on the matter | Abstentions: Against”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
James VollinsGeneral Counsel2023-04-30A120,000$0$0Derivative, Class A CommonForm 4 ↗
David ApelianDirector2023-07-03A750,00000Derivative, Class A CommonForm 4 ↗
Ingrid ChoongChief Business Officer2023-08-31A54,00000Derivative, Class A CommonForm 4 ↗
Leen KawasGreater-than-10% holder2023-10-31A12,34503,228Common, indirectForm 4 ↗
Leen KawasGreater-than-10% holder2023-10-31A11,98703,147Common, indirectForm 4 ↗
Richard A. KayneGreater-than-10% holder2023-10-31A130,509031,505Common, indirectForm 4 ↗
Richard A. KayneGreater-than-10% holder2023-10-31A12,34503,228Common, indirectForm 4 ↗
Richard A. KayneGreater-than-10% holder2023-10-31A11,98703,147Common, indirectForm 4 ↗
Richard A. KayneGreater-than-10% holder2023-11-01A100,000027,970Common, indirectForm 4 ↗
Richard A. KayneGreater-than-10% holder2023-11-02A23,39806,966Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (32 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, David Cory. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 3,683,861. View filing ↗
  • Section 01, Sriram Ryali. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 1,291,946. View filing ↗
  • Section 01, Eldon Mayer. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 981,007. View filing ↗
  • Section 01, David Apelian. DEF 14A, filed 2023-04-26. Section “Executive Compensation”. As printed: 204,386. View filing ↗
  • Section 03, David Apelian OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, David Cory OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Eldon Mayer OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Eldon Mayer OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Sriram Ryali OPTION. DEF 14A, filed 2023-04-26. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 08, Thomas Dietz, Ph.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 274,580. View filing ↗
  • Section 08, Lisa Kelly-Croswell. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 181,068. View filing ↗
  • Section 08, Evan Loh, M.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 137,090. View filing ↗
  • Section 08, Amit K. Sachdev, J.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 135,090. View filing ↗
  • Section 08, Jeffrey Glenn, M.D., Ph.D. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 134,590. View filing ↗
  • Section 08, Christine Murray, M.S., R.A.C. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 132,090. View filing ↗
  • Section 08, Kim Sablich, M.B.A. DEF 14A, filed 2023-04-26. Section “Director Compensation”. As printed: 124,590. View filing ↗
  • Section 02, James Vollins 2023-04-30. Form 4, filed 2023-05-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Apelian 2023-07-03. Form 4, filed 2023-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ingrid Choong 2023-08-31. Form 4, filed 2023-09-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Leen Kawas 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Leen Kawas 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Kayne 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Kayne 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Kayne 2023-10-31. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Kayne 2023-11-01. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Kayne 2023-11-02. Form 4, filed 2023-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-20. Item 5.07 · say-on-pay result. As reported: 38.72% (votes for as printed: 9,827,476). View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-06-21. Item 5.07 · say-on-pay result. As reported: 64.01% (votes for as printed: 16,752,944). View filing ↗
  • Section 06, 2021 vote. Form 8-K, filed 2021-06-15. Item 5.07 · say-on-pay result. As reported: 95.26% (votes for as printed: 19,555,119). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 518,000 + equity 183,600 + all other 0 = 701,600, summed across the director compensation table rows.
  • Eiger BioPharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-04-26. CEO total compensation as printed in Eiger BioPharmaceuticals, Inc.'s own proxy. As printed: 204,386. View filing ↗